Login Register Cart 0
Current Alzheimer Research

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Translate in Chinese
Review Article

Exploring the Interconnections of Genetic, Lifestyle, and Epigenetic Influences on Brain Aging: A Comprehensive Review

Author(s): Shima Mehrabadi* and Sama Barati

Volume 22, Issue 7, 2025

Published on: 01 August, 2025

Page: [488 - 501] Pages: 14

DOI: 10.2174/0115672050393583250718145103

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. The etiology of AD is complex and multifactorial, with contributions from genetic, lifestyle, and environmental factors. Recent advances in genetics, epigenetics, and animal models have shed light on the underlying mechanisms of brain aging and the development of AD, revealing potential targets for therapeutic intervention. In this comprehensive review, we examine the current understanding of the genetic, lifestyle, and epigenetic factors that shape the landscape of brain aging and AD. We discuss recent findings in the field of AD genetics, including the role of the APOE gene, and the potential of novel genome-wide association studies to identify new genetic risk factors. We also review the impact of lifestyle factors, such as diet, exercise, and social engagement, on brain aging and AD, and explore the role of epigenetic mechanisms, such as DNA methylation and histone modifications, in shaping AD risk.

Keywords: Alzheimer's disease, genetics, lifestyle factors, epigenetics, dementia, APOE.

« Previous Next »
[1]
Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimers Dis 2021; 8(3): 313-21.
[http://dx.doi.org/10.14283/jpad.2021.15] [PMID: 34101789]
[2]
A Armstrong R. Risk factors for Alzheimer’s disease. Folia Neuropathol 2019; 57(2): 87-105.
[http://dx.doi.org/10.5114/fn.2019.85929] [PMID: 31556570]
[3]
Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 2021; 20(1): 68-80.
[http://dx.doi.org/10.1016/S1474-4422(20)30412-9] [PMID: 33340485]
[4]
Jiang T, Yu JT, Tian Y, Tan L. Epidemiology and etiology of Alzheimer’s disease: From genetic to non-genetic factors. Curr Alzheimer Res 2013; 10(8): 852-67.
[http://dx.doi.org/10.2174/15672050113109990155] [PMID: 23919770]
[5]
Pan G, King A, Wu F, et al. The potential roles of genetic factors in predicting ageing-related cognitive change and Alzheimer’s disease. Ageing Res Rev 2021; 70: 101402.
[http://dx.doi.org/10.1016/j.arr.2021.101402] [PMID: 34242808]
[6]
De Plano LM, Saitta A, Oddo S, Caccamo A. Epigenetic changes in Alzheimer’s disease: DNA methylation and histone modification. Cells 2024; 13(8): 719.
[http://dx.doi.org/10.3390/cells13080719] [PMID: 38667333]
[7]
Migliore L, Coppedè F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 2009; 667(1-2): 82-97.
[http://dx.doi.org/10.1016/j.mrfmmm.2008.10.011] [PMID: 19026668]
[8]
Nakai T, Yamada K, Mizoguchi H. Alzheimer’s disease animal models: Elucidation of biomarkers and therapeutic approaches for cognitive impairment. Int J Mol Sci 2021; 22(11): 5549.
[http://dx.doi.org/10.3390/ijms22115549] [PMID: 34074018]
[9]
Bellenguez C, Grenier-Boley B, Lambert JC. Genetics of Alzheimer’s disease: Where we are, and where we are going. Curr Opin Neurobiol 2020; 61: 40-8.
[http://dx.doi.org/10.1016/j.conb.2019.11.024] [PMID: 31863938]
[10]
Stevenson-Hoare J, Heslegrave A, Leonenko G, et al. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s disease. Brain 2023; 146(2): 690-9.
[http://dx.doi.org/10.1093/brain/awac128] [PMID: 35383826]
[11]
Gal J, Katsumata Y, Zhu H, et al. Apolipoprotein E proteinopathy is a major dementia-associated pathologic biomarker in individuals with or without the APOE epsilon 4 Allele. Am J Pathol 2022; 192(3): 564-78.
[http://dx.doi.org/10.1016/j.ajpath.2021.11.013] [PMID: 34954207]
[12]
Qian J, Betensky RA, Hyman BT, Serrano-Pozo A. Association of APOE genotype with heterogeneity of cognitive decline rate in Alzheimer disease. Neurology 2021; 96(19): e2414-28.
[http://dx.doi.org/10.1212/WNL.0000000000011883] [PMID: 33771840]
[13]
Santos LR, Almeida JFF, Pimassoni LHS, Morelato RL, Paula F. The combined risk effect among BIN1, CLU, and APOE genes in Alzheimer’s disease. Genet Mol Biol 2020; 43(1): e20180320.
[http://dx.doi.org/10.1590/1678-4685-gmb-2018-0320] [PMID: 31469155]
[14]
Abd Elrahman HG, Ramadan A, Saleh EM, Saleh AA, Sabry NA, Mohamed MR. Association study of polymorphisms in ABCA7, clusterin, and MS4A6A genes with Alzheimer’s disease in the egyptian population. Turk Biyokim Derg 2020; 45(6): 757-65.
[http://dx.doi.org/10.1515/tjb-2020-0135]
[15]
Hamilton LK, Moquin-Beaudry G, Mangahas CL, et al. Stearoyl-CoA desaturase inhibition reverses immune, synaptic and cognitive impairments in an Alzheimer’s disease mouse model. Nat Commun 2022; 13(1): 2061.
[http://dx.doi.org/10.1038/s41467-022-29506-y] [PMID: 35443751]
[16]
Bello-Medina PC, González-Franco DA, Vargas-Rodríguez I, Díaz-Cintra S. Oxidative stress, the immune response, synaptic plasticity, and cognition in transgenic models of Alzheimer disease. Neurología 2022; 37: 682-90.
[http://dx.doi.org/10.1016/j.nrl.2019.06.002]
[17]
Chandy T. Intervention of next-generation sequencing in diagnosis of Alzheimer’s disease: Challenges and future prospects. Dement Neuropsychol 2023; 17: e20220025.
[http://dx.doi.org/10.1590/1980-5764-dn-2022-0025] [PMID: 37577182]
[18]
Shademan B, Biray Avci C, Nikanfar M, Nourazarian A. Application of next-generation sequencing in neurodegenerative diseases: Opportunities and challenges. Neuromolecular Med 2021; 23(2): 225-35.
[http://dx.doi.org/10.1007/s12017-020-08601-7] [PMID: 32399804]
[19]
Shigemizu D, Asanomi Y, Akiyama S, Mitsumori R, Niida S, Ozaki K. Whole-genome sequencing reveals novel ethnicity-specific rare variants associated with Alzheimer’s disease. Mol Psychiatry 2022; 27(5): 2554-62.
[http://dx.doi.org/10.1038/s41380-022-01483-0] [PMID: 35264725]
[20]
Clark K, Leung YY, Lee WP, Voight B, Wang LS. Polygenic risk scores in Alzheimer’s disease genetics: Methodology, applications, inclusion, and diversity. J Alzheimers Dis 2022; 89(1): 1-12.
[http://dx.doi.org/10.3233/JAD-220025] [PMID: 35848019]
[21]
Baker E, Escott-Price V. Polygenic risk scores in Alzheimer’s disease: Current applications and future directions. Front Digit Health 2020; 2: 14.
[http://dx.doi.org/10.3389/fdgth.2020.00014] [PMID: 34713027]
[22]
Rubinski A, Frerich S, Malik R, et al. Polygenic effect on tau pathology progression in Alzheimer’s disease. Ann Neurol 2023; 93(4): 819-29.
[http://dx.doi.org/10.1002/ana.26588] [PMID: 36571564]
[23]
Chacko L, Chaudhary A, Singh B, Dewanjee S, Kandimalla R. CRISPR-Cas9 in Alzheimer’s disease: Therapeutic trends, modalities, and challenges. Drug Discov Today 2023; 28(8): 103652.
[http://dx.doi.org/10.1016/j.drudis.2023.103652] [PMID: 37290639]
[24]
Michaelson DM. APOE ε4: The most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimers Dement 2014; 10(6): 861-8.
[http://dx.doi.org/10.1016/j.jalz.2014.06.015] [PMID: 25217293]
[25]
Cacciaglia R, Molinuevo JL, Falcón C, et al. Effects of APOE -ε4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer’s disease. Alzheimers Dement 2018; 14(7): 902-12.
[http://dx.doi.org/10.1016/j.jalz.2018.01.016] [PMID: 29605385]
[26]
Teter B, Campagna J, Zhu C, McCauley GE, Spilman P, Kohn DB, et al. Successful gene editing of apolipoprotein E4 to E3 in brain of Alzheimer model mice after a single IV dose of synthetic exosome-delivered CRISPR. bioRxiv 2024.04.2024;
[http://dx.doi.org/10.1101/2024.04.23.590784]
[27]
Cuyvers E, Sleegers K. Genetic variations underlying Alzheimer’s disease: Evidence from genome-wide association studies and beyond. Lancet Neurol 2016; 15(8): 857-68.
[http://dx.doi.org/10.1016/S1474-4422(16)00127-7] [PMID: 27302364]
[28]
Escott-Price V, Hardy J. Genome-wide association studies for Alzheimer’s disease: Bigger is not always better. Brain Commun 2022; 4(3): fcac125.
[http://dx.doi.org/10.1093/braincomms/fcac125] [PMID: 35663382]
[29]
Kamboh MI, Demirci FY, Wang X, et al. Genome-wide association study of Alzheimer’s disease. Transl Psychiatry 2012; 2(5): e117.
[http://dx.doi.org/10.1038/tp.2012.45] [PMID: 22832961]
[30]
Shen L, Jia J. An overview of genome-wide association studies in Alzheimer’s disease. Neurosci Bull 2016; 32(2): 183-90.
[http://dx.doi.org/10.1007/s12264-016-0011-3] [PMID: 26810783]
[31]
Arora S, Santiago JA, Bernstein M, Potashkin JA. Diet and lifestyle impact the development and progression of Alzheimer’s dementia. Front Nutr 2023; 10: 1213223.
[http://dx.doi.org/10.3389/fnut.2023.1213223] [PMID: 37457976]
[32]
Khemka S, Reddy A, Garcia RI, et al. Role of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases. Ageing Res Rev 2023; 91: 102091.
[http://dx.doi.org/10.1016/j.arr.2023.102091] [PMID: 37832608]
[33]
Everly J, Plummer J, Lohman M, Neils-Strunjas J. A tutorial for speech-language pathologists: Physical activity and social engagement to prevent or slow cognitive decline in older adults. Am J Speech Lang Pathol 2023; 32(1): 83-95.
[http://dx.doi.org/10.1044/2022_AJSLP-22-00035] [PMID: 36450149]
[34]
Ballarini T, Melo van Lent D, Brunner J, et al. Mediterranean diet, Alzheimer disease biomarkers, and brain atrophy in old age. Neurology 2021; 96(24): e2920-32.
[http://dx.doi.org/10.1212/WNL.0000000000012067] [PMID: 33952652]
[35]
Guasch-Ferré M, Willett WC. The mediterranean diet and health: A comprehensive overview. J Intern Med 2021; 290(3): 549-66.
[http://dx.doi.org/10.1111/joim.13333] [PMID: 34423871]
[36]
Yu F, Vock DM, Zhang L, et al. Cognitive effects of aerobic exercise in Alzheimer’s disease: A pilot randomized controlled trial. J Alzheimers Dis 2021; 80(1): 233-44.
[http://dx.doi.org/10.3233/JAD-201100] [PMID: 33523004]
[37]
Zimand Sheiner D, Kol O, Levy S. It makes a difference! Impact of social and personal message appeals on engagement with sponsored posts. J Res Interact Mark 2021; 15(4): 641-60.
[http://dx.doi.org/10.1108/JRIM-12-2019-0210]
[38]
Xygkou A, Ang CS, Siriaraya P, Kopecki JP, Covaci A, Kanjo E, et al. MindTalker: Navigating the Complexities of AI-Enhanced social engagement for people with early-stage dementia. Proceedings of the CHI Conference on Human Factors in Computing Systems. 2024 May 11 (pp. 1-15)
[http://dx.doi.org/10.1145/3613904.3642538]
[39]
Zheng D, Yuan X, Ma C, et al. Alcohol consumption and sleep quality: A community-based study. Public Health Nutr 2021; 24(15): 4851-8.
[http://dx.doi.org/10.1017/S1368980020004553] [PMID: 33183388]
[40]
Du C, Zan MCH, Cho MJ, et al. The effects of sleep quality and resilience on perceived stress, dietary behaviors, and alcohol misuse: a mediation-moderation analysis of higher education students from Asia, Europe, and North America during the COVID-19 pandemic. Nutrients 2021; 13(2): 442.
[http://dx.doi.org/10.3390/nu13020442] [PMID: 33572863]
[41]
Sun YY, Wang Z, Zhou HY, Huang HC. Sleep–wake disorders in Alzheimer’s disease: A review. ACS Chem Neurosci 2022; 13(10): 1467-78.
[http://dx.doi.org/10.1021/acschemneuro.2c00097] [PMID: 35507669]
[42]
Juszczyk G, Mikulska J, Kasperek K, Pietrzak D, Mrozek W, Herbet M. Chronic stress and oxidative stress as common factors of the pathogenesis of depression and Alzheimer’s disease: The role of antioxidants in prevention and treatment. Antioxidants 2021; 10(9): 1439.
[http://dx.doi.org/10.3390/antiox10091439] [PMID: 34573069]
[43]
Machado A, Herrera AJ, de Pablos RM, et al. Chronic stress as a risk factor for Alzheimer’s disease. Rev Neurosci 2014; 25(6): 785-804.
[http://dx.doi.org/10.1515/revneuro-2014-0035] [PMID: 25178904]
[44]
Bisht K, Sharma K, Tremblay MÈ. Chronic stress as a risk factor for Alzheimer’s disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress. Neurobiol Stress 2018; 9: 9-21.
[http://dx.doi.org/10.1016/j.ynstr.2018.05.003] [PMID: 29992181]
[45]
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y) 2018; 4(1): 575-90.
[http://dx.doi.org/10.1016/j.trci.2018.06.014] [PMID: 30406177]
[46]
McGrattan AM, McGuinness B, McKinley MC, et al. Diet and inflammation in cognitive ageing and Alzheimer’s disease. Curr Nutr Rep 2019; 8(2): 53-65.
[http://dx.doi.org/10.1007/s13668-019-0271-4] [PMID: 30949921]
[47]
Kaddoumi A, Denney TS Jr, Deshpande G, et al. Extra-virgin olive oil enhances the blood–brain barrier function in mild cognitive impairment: A randomized controlled trial. Nutrients 2022; 14(23): 5102.
[http://dx.doi.org/10.3390/nu14235102] [PMID: 36501136]
[48]
Xie Y, Yan L, Zeng H, et al. Fish oil protects the blood–brain barrier integrity in a mouse model of Alzheimer’s disease. Chin Med 2020; 15(1): 29.
[http://dx.doi.org/10.1186/s13020-020-00314-0] [PMID: 32256685]
[49]
Na SY, Janakiraman M, Leliavski A, Krishnamoorthy G. High-salt diet suppresses autoimmune demyelination by regulating the blood–brain barrier permeability. Proc Natl Acad Sci USA 2021; 118(12): e2025944118.
[http://dx.doi.org/10.1073/pnas.2025944118] [PMID: 33723078]
[50]
Teymoori F, Farhadnejad H, Moslehi N, Mirmiran P, Mokhtari E, Azizi F. The association of dietary insulin and glycemic indices with the risk of type 2 diabetes. Clin Nutr 2021; 40(4): 2138-44.
[http://dx.doi.org/10.1016/j.clnu.2020.09.038] [PMID: 33092900]
[51]
Cui Y, Tang TY, Lu CQ, Ju S. Insulin resistance and cognitive impairment: Evidence from neuroimaging. J Magn Reson Imaging 2022; 56(6): 1621-49.
[http://dx.doi.org/10.1002/jmri.28358] [PMID: 35852470]
[52]
Picone P, Di Carlo M, Nuzzo D. Obesity and Alzheimer’s disease: Molecular bases. Eur J Neurosci 2020; 52(8): 3944-50.
[http://dx.doi.org/10.1111/ejn.14758] [PMID: 32323378]
[53]
Khan MSH, Hegde V. Obesity and diabetes mediated chronic inflammation: A potential biomarker in Alzheimer’s disease. J Pers Med 2020; 10(2): 42.
[http://dx.doi.org/10.3390/jpm10020042] [PMID: 32455946]
[54]
Wei BZ, Li L, Dong CW, Tan CC, Xu W. The relationship of omega-3 fatty acids with dementia and cognitive decline: Evidence from prospective cohort studies of supplementation, dietary intake, and blood markers. Am J Clin Nutr 2023; 117(6): 1096-109.
[http://dx.doi.org/10.1016/j.ajcnut.2023.04.001] [PMID: 37028557]
[55]
Sheng LT, Jiang YW, Pan XF, et al. Association between dietary intakes of B vitamins in midlife and cognitive impairment in late-life: The singapore chinese health study. J Gerontol A Biol Sci Med Sci 2020; 75(6): 1222-7.
[http://dx.doi.org/10.1093/gerona/glz125] [PMID: 31094422]
[56]
Pritam P, Deka R, Bhardwaj A, et al. Antioxidants in Alzheimer’s disease: Current therapeutic significance and future prospects. Biology 2022; 11(2): 212.
[http://dx.doi.org/10.3390/biology11020212] [PMID: 35205079]
[57]
Zhu L, Li L, Wang L, Jin X, Zhang H. Physical activity for executive function and activities of daily living in AD patients: A systematic review and meta-analysis. Front Psychol 2020; 11: 560461.
[http://dx.doi.org/10.3389/fpsyg.2020.560461] [PMID: 33343442]
[58]
Hoffmann CM, Petrov ME, Lee RE. Aerobic physical activity to improve memory and executive function in sedentary adults without cognitive impairment: A systematic review and meta-analysis. Prev Med Rep 2021; 23: 101496.
[http://dx.doi.org/10.1016/j.pmedr.2021.101496] [PMID: 34377632]
[59]
Ribarič S. Physical exercise, a potential non-pharmacological intervention for attenuating neuroinflammation and cognitive decline in Alzheimer’s disease patients. Int J Mol Sci 2022; 23(6): 3245.
[http://dx.doi.org/10.3390/ijms23063245] [PMID: 35328666]
[60]
Wang M, Zhang H, Liang J, Huang J, Chen N. Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease. J Neuroinflammation 2023; 20(1): 76.
[http://dx.doi.org/10.1186/s12974-023-02753-6] [PMID: 36935511]
[61]
Liu W, Zhang J, Wang Y, Li J, Chang J, Jia Q. Effect of physical exercise on cognitive function of Alzheimer’s disease patients: A systematic review and meta-analysis of randomized controlled trial. Front Psychiatry 2022; 13: 927128.
[http://dx.doi.org/10.3389/fpsyt.2022.927128] [PMID: 35782450]
[62]
Gaitán JM, Moon HY, Stremlau M, et al. Effects of aerobic exercise training on systemic biomarkers and cognition in late middle-aged adults at risk for Alzheimer’s disease. Front Endocrinol (Lausanne) 2021; 12: 660181.
[http://dx.doi.org/10.3389/fendo.2021.660181] [PMID: 34093436]
[63]
Chen WW, Zhang X, Huang WJ. Role of physical exercise in Alzheimer’s disease. Biomed Rep 2016; 4(4): 403-7.
[http://dx.doi.org/10.3892/br.2016.607] [PMID: 27073621]
[64]
Biddle KD, d’Oleire Uquillas F, Jacobs HIL, et al. Social engagement and amyloid-β-related cognitive decline in cognitively normal older adults. Am J Geriatr Psychiatry 2019; 27(11): 1247-56.
[http://dx.doi.org/10.1016/j.jagp.2019.05.005] [PMID: 31248770]
[65]
Sposito G, Neri AL, Yassuda MS. Cognitive performance and engagement in physical, social and intellectual activities in older adults: The Fibra study. Dement Neuropsychol 2015; 9(3): 270-8.
[http://dx.doi.org/10.1590/1980-57642015dn93000010] [PMID: 29213972]
[66]
Zhou S, Song S, Jin Y, Zheng ZJ. Prospective association between social engagement and cognitive impairment among middle-aged and older adults: evidence from the China Health and Retirement Longitudinal Study. BMJ Open 2020; 10(11): e040936.
[http://dx.doi.org/10.1136/bmjopen-2020-040936] [PMID: 33208332]
[67]
Phillips C. Lifestyle modulators of neuroplasticity: how physical activity, mental engagement, and diet promote cognitive health during aging. Neural Plast 2017; 2017: 1-22.
[http://dx.doi.org/10.1155/2017/3589271] [PMID: 28695017]
[68]
Opendak M, Briones BA, Gould E. Social behavior, hormones and adult neurogenesis. Front Neuroendocrinol 2016; 41: 71-86.
[http://dx.doi.org/10.1016/j.yfrne.2016.02.002] [PMID: 26996817]
[69]
Colonnello V, Petrocchi N, Farinelli M, Ottaviani C. Positive social interactions in a lifespan perspective with a focus on opioidergic and oxytocinergic systems: Implications for neuroprotection. Curr Neuropharmacol 2017; 15(4): 543-61.
[http://dx.doi.org/10.2174/1570159X14666160816120209] [PMID: 27538784]
[70]
Nucci D, Sommariva A, Degoni LM, et al. Association between mediterranean diet and dementia and Alzheimer disease: A systematic review with meta-analysis. Aging Clin Exp Res 2024; 36(1): 77.
[http://dx.doi.org/10.1007/s40520-024-02718-6] [PMID: 38519775]
[71]
Trabado-Fernández A, García-Colomo A, Cuadrado-Soto E, et al. Association of a Dash diet and magnetoencephalography in dementia-free adults with different risk levels of Alzheimer’s disease. Geroscience 2024; 47(2): 1747-59.
[http://dx.doi.org/10.1007/s11357-024-01361-3] [PMID: 39354239]
[72]
Bransby L, Buckley RF, Rosenich E, et al. The relationship between cognitive engagement and better memory in midlife. Alzheimers Dement 2022; 14(1): e12278.
[http://dx.doi.org/10.1002/dad2.12278] [PMID: 35155733]
[73]
Casagrande M, Forte G, Favieri F, Corbo I. Sleep quality and aging: A systematic review on healthy older people, mild cognitive impairment and Alzheimer’s disease. Int J Environ Res Public Health 2022; 19(14): 8457.
[http://dx.doi.org/10.3390/ijerph19148457] [PMID: 35886309]
[74]
Mohammadi S, Zandi M, Kataj PD, Zandi LK. Chronic stress and Alzheimer’s disease. Biotechnol Appl Biochem 2022; 69(4): 1451-8.
[http://dx.doi.org/10.1002/bab.2216] [PMID: 34152660]
[75]
Xie C, Feng Y. Alcohol consumption and risk of Alzheimer’s disease: A dose–response meta-analysis. Geriatr Gerontol Int 2022; 22(4): 278-85.
[http://dx.doi.org/10.1111/ggi.14357] [PMID: 35171516]
[76]
Durazzo TC, Mattsson N, Weiner MW. Smoking and increased Alzheimer’s disease risk: A review of potential mechanisms. Alzheimers Dement 2014; 10(3Suppl): S122-45.
[http://dx.doi.org/10.1016/j.jalz.2014.04.009] [PMID: 24924665]
[77]
Mehrabadi S. Effects of chronic administration of nickel on memory function, hippocampal neuronal morphology and oxidative stress factors in male adult rats. Arch Adv Biosci 2022; 13: 1-8.
[http://dx.doi.org/10.22037/aab.v13i2.35890]
[78]
Olayinka O, Olayinka OO, Alemu BT, Akpinar-Elci M, Grossberg GT. Toxic environmental risk factors for Alzheimer’s disease: A systematic review. Aging Med Healthc 2019; 10(1): 4-17.
[http://dx.doi.org/10.33879/amh.2019.1727]
[79]
Yegambaram M, Manivannan B, Beach T, Halden R. Role of environmental contaminants in the etiology of Alzheimer’s disease: A review. Curr Alzheimer Res 2015; 12(2): 116-46.
[http://dx.doi.org/10.2174/1567205012666150204121719] [PMID: 25654508]
[80]
Mir RH, Sawhney G, Pottoo FH, et al. Role of environmental pollutants in Alzheimer’s disease: A review. Environ Sci Pollut Res Int 2020; 27(36): 44724-42.
[http://dx.doi.org/10.1007/s11356-020-09964-x] [PMID: 32715424]
[81]
Tecalco-Cruz AC, Ramírez-Jarquín JO, Alvarez-Sánchez ME, Zepeda-Cervantes J. Epigenetic basis of Alzheimer disease. World J Biol Chem 2020; 11(2): 62-75.
[http://dx.doi.org/10.4331/wjbc.v11.i2.62] [PMID: 33024518]
[82]
Nikolac Perkovic M, Paska AV, Konjevod M, et al. Epigenetics of Alzheimer’s disease. Biomolecules 2021; 11(2): 195.
[http://dx.doi.org/10.3390/biom11020195] [PMID: 33573255]
[83]
Poon CH, Tse LSR, Lim LW. DNA methylation in the pathology of Alzheimer’s disease: From gene to cognition. Ann N Y Acad Sci 2020; 1475(1): 15-33.
[http://dx.doi.org/10.1111/nyas.14373] [PMID: 32491215]
[84]
Castillo-Ordoñez WO, Cajas-Salazar N, Velasco-Reyes MA. Genetic and epigenetic targets of natural dietary compounds as anti-Alzheimer’s agents. Neural Regen Res 2024; 19(4): 846-54.
[http://dx.doi.org/10.4103/1673-5374.382232] [PMID: 37843220]
[85]
Vetter VM, Drewelies J, Sommerer Y, et al. Epigenetic aging and perceived psychological stress in old age. Transl Psychiatry 2022; 12(1): 410.
[http://dx.doi.org/10.1038/s41398-022-02181-9] [PMID: 36163242]
[86]
Migliore L, Coppedè F. Gene–environment interactions in Alzheimer disease: The emerging role of epigenetics. Nat Rev Neurol 2022; 18(11): 643-60.
[http://dx.doi.org/10.1038/s41582-022-00714-w] [PMID: 36180553]
[87]
Lin FC, Chen CY, Lin CW, Wu MT, Chen HY, Huang P. Air pollution is associated with cognitive deterioration of Alzheimer’s disease. Gerontology 2022; 68(1): 53-61.
[http://dx.doi.org/10.1159/000515162] [PMID: 33882496]
[88]
Atluri VSR, Tiwari S, Rodriguez M, et al. Inhibition of amyloid-beta production, associated neuroinflammation, and histone deacetylase 2-mediated epigenetic modifications prevent neuropathology in Alzheimer’s disease in vitro model. Front Aging Neurosci 2020; 11: 342.
[http://dx.doi.org/10.3389/fnagi.2019.00342] [PMID: 32009938]
[89]
Kaur G, Rathod SSS, Ghoneim MM, et al. DNA methylation: A promising approach in management of Alzheimer’s disease and other neurodegenerative disorders. Biology 2022; 11(1): 90.
[http://dx.doi.org/10.3390/biology11010090] [PMID: 35053088]
[90]
Paniri A, Hosseini MM, Akhavan-Niaki H. Alzheimer’s disease-related epigenetic changes: Novel therapeutic targets. Mol Neurobiol 2024; 61(3): 1282-317.
[http://dx.doi.org/10.1007/s12035-023-03626-y] [PMID: 37700216]
[91]
Villa C, Stoccoro A. Epigenetic peripheral biomarkers for early diagnosis of Alzheimer’s disease. Genes 2022; 13(8): 1308.
[http://dx.doi.org/10.3390/genes13081308] [PMID: 35893045]
[92]
Xiao X, Liu X, Jiao B. Epigenetics: Recent advances and its role in the treatment of Alzheimer’s disease. Front Neurol 2020; 11: 538301.
[http://dx.doi.org/10.3389/fneur.2020.538301] [PMID: 33178099]
[93]
Wei X, Zhang L, Zeng Y. DNA methylation in Alzheimer’s disease: In brain and peripheral blood. Mech Ageing Dev 2020; 191: 111319.
[http://dx.doi.org/10.1016/j.mad.2020.111319] [PMID: 32721406]
[94]
Shi Z, Zhang K, Zhou H, et al. Increased miR-34c mediates synaptic deficits by targeting synaptotagmin 1 through ROS-JNK-p53 pathway in Alzheimer’s Disease. Aging Cell 2020; 19(3): e13125.
[http://dx.doi.org/10.1111/acel.13125] [PMID: 32092796]
[95]
Sae-Lee C, Biasi JD, Robinson N, et al. DNA methylation patterns of LINE-1 and Alu for pre-symptomatic dementia in type 2 diabetes. PLoS One 2020; 15(6): e0234578.
[http://dx.doi.org/10.1371/journal.pone.0234578] [PMID: 32525932]
[96]
Koenigsberg SH, Chang CJ, Ish J, et al. Air pollution and epigenetic aging among Black and White women in the US. Environ Int 2023; 181: 108270.
[http://dx.doi.org/10.1016/j.envint.2023.108270] [PMID: 37890265]
[97]
Wood IC. The contribution and therapeutic potential of epigenetic modifications in Alzheimer’s disease. Front Neurosci 2018; 12: 649.
[http://dx.doi.org/10.3389/fnins.2018.00649] [PMID: 30283297]
[98]
Cherblanc F, Chapman-Rothe N, Brown R, Fuchter MJ. Current limitations and future opportunities for epigenetic therapies. Future Med Chem 2012; 4(4): 425-46.
[http://dx.doi.org/10.4155/fmc.12.7] [PMID: 22416773]
[99]
Dawson MA. The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science 2017; 355(6330): 1147-52.
[http://dx.doi.org/10.1126/science.aam7304] [PMID: 28302822]
[100]
Li Q, Lei Y, Zhang P, Liu Y, Lu Q, Chang C. Future challenges and prospects for personalized epigenetics. In: Tollefsbol T, Ed. Translational Epigenetics, Personalized Epigenetics (Second Edition). Academic Press 2024; pp. 721-44.
[http://dx.doi.org/10.1016/B978-0-443-23802-4.00019-3]
[101]
Zhong MZ, Peng T, Duarte ML, Wang M, Cai D. Updates on mouse models of Alzheimer’s disease. Mol Neurodegener 2024; 19(1): 23.
[http://dx.doi.org/10.1186/s13024-024-00712-0] [PMID: 38462606]
[102]
B Szabo A, Cattaud V, Bezzina C, et al. Neuronal hyperexcitability in the Tg2576 mouse model of Alzheimer’s disease - the influence of sleep and noradrenergic transmission. Neurobiol Aging 2023; 123: 35-48.
[http://dx.doi.org/10.1016/j.neurobiolaging.2022.11.017] [PMID: 36634385]
[103]
Evans CE, Miners JS, Piva G, et al. ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease. Acta Neuropathol 2020; 139(3): 485-502.
[http://dx.doi.org/10.1007/s00401-019-02098-6] [PMID: 31982938]
[104]
Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular abeta and synaptic dysfunction. Neuron 2003; 39(3): 409-21.
[http://dx.doi.org/10.1016/S0896-6273(03)00434-3] [PMID: 12895417]
[105]
Pádua MS, Guil-Guerrero JL, Prates JAM, Lopes PA. Insights on the use of transgenic mice models in Alzheimer’s disease research. Int J Mol Sci 2024; 25(5): 2805.
[http://dx.doi.org/10.3390/ijms25052805] [PMID: 38474051]
[106]
Choe MS, Yeo HC, Kim JS, et al. Simple modeling of familial Alzheimer’s disease using human pluripotent stem cell-derived cerebral organoid technology. Stem Cell Res Ther 2024; 15(1): 118.
[http://dx.doi.org/10.1186/s13287-024-03732-1] [PMID: 38659053]
[107]
Langeland JA, Baumann L, DeYoung EM, et al. Early animal origin of BACE1 APP/Aβ proteolytic function. Biology 2024; 13(5): 320.
[http://dx.doi.org/10.3390/biology13050320] [PMID: 38785802]
[108]
Ohno M. A strategy for allowing earlier diagnosis and rigorous evaluation of BACE1 inhibitors in preclinical Alzheimer’s disease. J Alzheimers Dis 2024; 99(2): 431-45.
[http://dx.doi.org/10.3233/JAD-231451] [PMID: 38701146]
[109]
Hooijmans CR, Pasker-de Jong PCM, de Vries RBM, Ritskes-Hoitinga M. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer’s pathology in animal models of Alzheimer’s disease: A systematic review and meta-analysis. J Alzheimers Dis 2012; 28(1): 191-209.
[http://dx.doi.org/10.3233/JAD-2011-111217] [PMID: 22002791]
[110]
García-Mesa Y, López-Ramos JC, Giménez-Llort L, et al. Physical exercise protects against Alzheimer’s disease in 3xTg-AD mice. J Alzheimers Dis 2011; 24(3): 421-54.
[http://dx.doi.org/10.3233/JAD-2011-101635] [PMID: 21297257]
[111]
Park YH, Shin SJ, Kim H, et al. Omega-3 fatty acid-type docosahexaenoic acid protects against Aβ-mediated mitochondrial deficits and pathomechanisms in Alzheimer’s disease-related animal model. Int J Mol Sci 2020; 21(11): 3879.
[http://dx.doi.org/10.3390/ijms21113879] [PMID: 32486013]
[112]
Singh N, Ghosh KK. Recent advances in the antioxidant therapies for Alzheimer’s disease: Emphasis on natural antioxidants. In: Singh S, Joshi N, Eds. Pathology, Prevention and Therapeutics of Neurodegenerative Disease. Singapore: Springer 2019.
[http://dx.doi.org/10.1007/978-981-13-0944-1_22]
[113]
Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 2010; 16(11): 1210-4.
[http://dx.doi.org/10.1038/nm.2224] [PMID: 21052075]
[114]
Laurijssens B, Aujard F, Rahman A. Animal models of Alzheimer’s disease and drug development. Drug Discov Today Technol 2013; 10(3): e319-27.
[http://dx.doi.org/10.1016/j.ddtec.2012.04.001] [PMID: 24050129]
[115]
Zhang L, Chen C, Mak MSH, et al. Advance of sporadic Alzheimer’s disease animal models. Med Res Rev 2020; 40(1): 431-58.
[http://dx.doi.org/10.1002/med.21624] [PMID: 31328804]
[116]
Cavanaugh SE, Pippin JJ, Barnard ND. Animal models of Alzheimer disease: Historical pitfalls and a path forward. Altern Anim Exp 2014; 31(3): 279-302.
[PMID: 24793844]
[117]
Drummond E, Wisniewski T. Alzheimer’s disease: Experimental models and reality. Acta Neuropathol 2017; 133(2): 155-75.
[http://dx.doi.org/10.1007/s00401-016-1662-x] [PMID: 28025715]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 22
Html icon 2
Find your institution